Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial

Ruizhi Zhang, Junshi Zhao, Xiaoping Zhu, Qinghu Guan, Shu‐Jun Liu, Ho‐Keung Ng, Jianghua Gao, Jie Tan, Feng Cao, Beifang Gan, Bo Wu, Jin Bai, Youquan Liu, Gang Xie, Chi Liu, Wei Zhao, Lixin Yan, Shuping Xu, Qian Gui, Dongfang Liu, Jian Li, Wei Li, Xuxin Tian, Jinling Wang, Shanshan Wang, Dongyang Li, Jing Li, Yuhuan Jiao, Xuefeng Li, Yuanxin Chen, Yang Wang, Wenlin Gai, Qiang Zhou, Liangzhi XieNature Communications 2024 · DOI

Abstract

The rapid evolution of SARS-CoV-2 variants emphasizes the need for multivalent vaccines capable of simultaneously targeting multiple strains. SCTV01E is a tetravalent COVID-19 vaccine derived from the spike protein of SARS-CoV-2 variants Alpha, Beta, Delta, and Omicron BA.1. In this double-blinded placebo-controlled pivotal efficacy trial (NCT05308576), the primary endpoint was vaccine efficacy (VE) against COVID-19 seven days post-vaccination in individuals without recent infection. Between December 26, 2022, and January 15, 2023, 9,223 individuals were randomized at a 1:1 ratio to receive SCTV01E or a placebo. SCTV01E showed a VE of 69.4% (95% CI: 50.6, 81.0) 7 days post-vaccination. VEs were 79.7% and 82.4%, respectively, for preventing symptomatic infection and all SARS-CoV-2 infections 14 days post-vaccination. Reactogenicity was generally mild and transient, with no reported vaccine-related serious adverse events (SAEs). These results suggest SCTV01E is a potential vaccine alternative effective against present and future variants.

Introduction

The rapid evolution of SARS-CoV-2 variants—from the original ancestral strain to the highly transmissible Omicron sublineages—has significantly eroded the protection offered by first-generation monovalent vaccines. While mRNA vaccines can be updated relatively quickly, they face challenges regarding cold-chain requirements and reactogenicity. Protein-based vaccines are generally more stable and better tolerated, but creating one that can "keep up" with viral evolution is difficult. SCTV01E addresses this by using a tetravalent approach, targeting the trimeric spike extracellular domain (S-ECD) from four variants: Alpha, Beta, Delta, and Omicron BA.1.

Methods

This Phase 3, double-blind, randomized, placebo-controlled trial was conducted across nine sites in China during a massive surge of Omicron subvariants. A total of 9,223 participants (18+ years old) were randomized 1:1 to receive either a single booster dose of SCTV01E or a saline placebo. Most participants had previously received primary series of inactivated vaccines.

To ensure results were not confounded by the massive wave of infections occurring during the trial, the primary analysis focused on a "Per-Protocol Efficacy" (PPE) set. This set excluded individuals who had high baseline anti-spike IgG levels (indicating recent prior infection) or positive PCR/antigen tests at the start of the study. The primary endpoint was vaccine efficacy (VE) against symptomatic COVID-19 starting 7 days post-vaccination.

Results

Vaccine Efficacy

SCTV01E demonstrated rapid and robust protection during an active outbreak. The primary endpoint of VE against symptomatic COVID-19 at 7 days post-vaccination was 69.4% (95% CI: 50.6, 81.0). When extending the observation window to 14 days post-vaccination, the VE increased to 79.7% against symptomatic infection and 82.4% against all SARS-CoV-2 infections (including asymptomatic cases).

Figure 5: Cumulative incidence of symptomatic COVID-19 starting 7 days post-vaccination, showing a primary vaccine efficacy of 69.4%.

Subgroup analyses confirmed that the vaccine's efficacy was consistent across various demographics, including age (18-59 vs. ≥60 years), sex, and the presence of pre-existing comorbidities. This consistency highlights the broad applicability of the SCTV01E booster.

Figure 6: Forest plot of subgroup analysis for vaccine efficacy (VE) against symptomatic COVID-19, demonstrating consistent protection across participant categories.

Immunogenicity and Safety

SCTV01E elicited a 25.0-fold higher neutralizing antibody response against Omicron BA.5 compared to the placebo group 28 days after injection. Furthermore, in "breakthrough" cases (vaccinated individuals who still contracted the virus), the median viral load was 47.9-fold lower than in the placebo group, suggesting that the vaccine significantly limits viral replication even when it does not prevent infection entirely.

The safety profile was favorable. While the vaccine group reported more solicited adverse events (16.8% vs 6.2% in placebo), these were primarily mild (Grade 1 or 2) injection site pain. There were no reported vaccine-related serious adverse events (SAEs), adverse events of special interest (AESI), or deaths.

Discussion

SCTV01E provides a viable, broad-spectrum alternative to current vaccines. A major logistical advantage is its stability; SCTV01E remained stable at 25°C (77°F) for over six months, making it a more viable option for resource-limited settings compared to mRNA vaccines requiring ultra-cold storage.

Limitations of the study include a relatively short observation window (approximately 4 months) due to the rapid accumulation of cases during the infection peak. Additionally, the use of a saline placebo rather than an active comparator was a limitation necessitated by the difficulty of sourcing licensed vaccines during the outbreak. Future work will need to confirm the long-term durability of this protection and the platform's efficacy against newer emerging variants like JN.1.

Summary updated

Abstract

Evolution of SARS-CoV-2 variants emphasizes the need for multivalent vaccines capable of simultaneously targeting multiple strains. SCTV01E is a tetravalent COVID-19 vaccine derived from the spike protein of SARS-CoV-2 variants Alpha, Beta, Delta, and Omicron BA.1. In this double-blinded placebo-controlled pivotal efficacy trial (NCT05308576), the primary endpoint was vaccine efficacy (VE) against COVID-19 seven days post-vaccination in individuals without recent infection. Other endpoints included evaluating safety, immunogenicity, and the VE against all SARS-CoV-2 infections in individuals meeting the study criteria. Between December 26, 2022, and January 15, 2023, 9,223 individuals were randomized at a 1:1 ratio to receive SCTV01E or a placebo. SCTV01E showed a VE of 69.4% (95% CI: 50.6, 81.0) 7 days post-vaccination, with 75 cases in the placebo group and 23 in the SCTV01E group for the primary endpoint. VEs were 79.7% (95% CI: 51.0, 91.6) and 82.4% (95% CI: 57.9, 92.6), respectively, for preventing symptomatic infection and all SARS-CoV-2 infections 14 days post-vaccination. SCTV01E elicited a 25.0-fold higher neutralizing antibody response against Omicron BA.5 28 days post-vaccination compared to placebo. Reactogenicity was generally mild and transient, with no reported vaccine-related SAE, adverse events of special interest (AESI), or deaths. The trial aligned with the shift from dominant variants BA.5 and BF.7 to XBB, suggesting SCTV01E as a potential vaccine alternative effective against present and future variants.
BibTeX
@inproceedings{zhang2024efficacy,
  author = {Ruizhi Zhang and Junshi Zhao and Xiaoping Zhu and Qinghu Guan and Shu‐Jun Liu and Ho‐Keung Ng and Jianghua Gao and Jie Tan and Feng Cao and Beifang Gan and Bo Wu and Jin Bai and Youquan Liu and Gang Xie and Chi Liu and Wei Zhao and Lixin Yan and Shuping Xu and Qian Gui and Dongfang Liu and Jian Li and Wei Li and Xuxin Tian and Jinling Wang and Shanshan Wang and Dongyang Li and Jing Li and Yuhuan Jiao and Xuefeng Li and Yuanxin Chen and Yang Wang and Wenlin Gai and Qiang Zhou and Liangzhi Xie},
  title = {{Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-49832-7},
}
Figure